VERICEL CORPORATION Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VERICEL CORPORATION stock issued during period, value, new issues for the quarter ending 2018-06-30 was $70.09M.
- VERICEL CORPORATION stock issued during period, value, new issues for fiscal 2018 was $70.03M, a 874.23% increase from fiscal 2017.
- VERICEL CORPORATION stock issued during period, value, new issues for fiscal 2017 was $7.19M, a 61.90% decline from fiscal 2016.
- VERICEL CORPORATION stock issued during period, value, new issues for fiscal 2016 was $18.87M.
- VERICEL CORPORATION stock issued during period, value, new issues for fiscal 2014 was $48.41M, a 582.39% increase from fiscal 2013.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2018-12-31 | $70.03M 10-K · filed 2021-02-24 | |
| 2018-06-30 | $70.09M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $7.19M 10-K · filed 2020-02-25 | |
| 2016-12-31 | $18.87M 10-K · filed 2019-02-26 | |
| 2014-12-31 | $48.41M 10-K · filed 2017-03-13 | |
| 2013-12-31 | $7.09M 10-K · filed 2015-03-25 | |
| 2012-12-31 | $10.51M 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |